Cargando…

Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset

Background: It has been recommended that any invasive treatment performed in patients with central serous chorioretinopathy (CSCR) not be initiated earlier than four months after disease onset due to the potential for spontaneous remission of symptoms. The goal of this study was to examine the outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Gawęcki, Maciej, Jaszczuk-Maciejewska, Agnieszka, Jurska-Jaśko, Anna, Kneba, Małgorzata, Grzybowski, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780961/
https://www.ncbi.nlm.nih.gov/pubmed/31500100
http://dx.doi.org/10.3390/jcm8091398
_version_ 1783457265499504640
author Gawęcki, Maciej
Jaszczuk-Maciejewska, Agnieszka
Jurska-Jaśko, Anna
Kneba, Małgorzata
Grzybowski, Andrzej
author_facet Gawęcki, Maciej
Jaszczuk-Maciejewska, Agnieszka
Jurska-Jaśko, Anna
Kneba, Małgorzata
Grzybowski, Andrzej
author_sort Gawęcki, Maciej
collection PubMed
description Background: It has been recommended that any invasive treatment performed in patients with central serous chorioretinopathy (CSCR) not be initiated earlier than four months after disease onset due to the potential for spontaneous remission of symptoms. The goal of this study was to examine the outcome of transfoveal subthreshold micropulse laser treatment (SMPLT) of CSCR performed at six months or less after disease onset. Materials and methods: The study included 32 cases of CSCR lasting between three weeks and six months (mean: 3.4 ± 2.3 months). All patients had transfoveal SMPLT applied and were followed for at least three months after each session of SMPLT. Two sessions of SMPLT in total were planned in case of an insufficient response to the first instance of treatment. Evaluation parameters included any change in best-corrected visual acuity (BCVA) and retinal morphology. Results: Total resolution of subretinal fluid (SRF) was noted in 26 cases (81.25%). Final BCVA improved significantly from 0.37 ± 0.22 logMAR to 0.22 ± 0.20 logMAR after treatment. Overall, early SMPLT correlated with better final BCVA (p = 0.0005, Spearman rank correlation). For eyes achieving a total resolution of SRF, BCVA improved from 0.33 ± 0.21 logMAR to 0.17 ± 0.14 logMAR (p = 0.004, Spearman rank correlation). The analysis of SMPLT nonresponders revealed a tendency for poorer baseline visual acuity. Conclusions: Patients with CSCR lasting six months or less treated with transfoveal SMPLT achieve better functional results with early application of this procedure. As baseline BCVA predicts final visual acuity, earlier treatment, permitted by the safety of SMPLT, may improve final visual outcomes.
format Online
Article
Text
id pubmed-6780961
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67809612019-10-30 Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset Gawęcki, Maciej Jaszczuk-Maciejewska, Agnieszka Jurska-Jaśko, Anna Kneba, Małgorzata Grzybowski, Andrzej J Clin Med Article Background: It has been recommended that any invasive treatment performed in patients with central serous chorioretinopathy (CSCR) not be initiated earlier than four months after disease onset due to the potential for spontaneous remission of symptoms. The goal of this study was to examine the outcome of transfoveal subthreshold micropulse laser treatment (SMPLT) of CSCR performed at six months or less after disease onset. Materials and methods: The study included 32 cases of CSCR lasting between three weeks and six months (mean: 3.4 ± 2.3 months). All patients had transfoveal SMPLT applied and were followed for at least three months after each session of SMPLT. Two sessions of SMPLT in total were planned in case of an insufficient response to the first instance of treatment. Evaluation parameters included any change in best-corrected visual acuity (BCVA) and retinal morphology. Results: Total resolution of subretinal fluid (SRF) was noted in 26 cases (81.25%). Final BCVA improved significantly from 0.37 ± 0.22 logMAR to 0.22 ± 0.20 logMAR after treatment. Overall, early SMPLT correlated with better final BCVA (p = 0.0005, Spearman rank correlation). For eyes achieving a total resolution of SRF, BCVA improved from 0.33 ± 0.21 logMAR to 0.17 ± 0.14 logMAR (p = 0.004, Spearman rank correlation). The analysis of SMPLT nonresponders revealed a tendency for poorer baseline visual acuity. Conclusions: Patients with CSCR lasting six months or less treated with transfoveal SMPLT achieve better functional results with early application of this procedure. As baseline BCVA predicts final visual acuity, earlier treatment, permitted by the safety of SMPLT, may improve final visual outcomes. MDPI 2019-09-06 /pmc/articles/PMC6780961/ /pubmed/31500100 http://dx.doi.org/10.3390/jcm8091398 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gawęcki, Maciej
Jaszczuk-Maciejewska, Agnieszka
Jurska-Jaśko, Anna
Kneba, Małgorzata
Grzybowski, Andrzej
Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset
title Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset
title_full Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset
title_fullStr Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset
title_full_unstemmed Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset
title_short Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset
title_sort transfoveal micropulse laser treatment of central serous chorioretinopathy within six months of disease onset
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780961/
https://www.ncbi.nlm.nih.gov/pubmed/31500100
http://dx.doi.org/10.3390/jcm8091398
work_keys_str_mv AT gaweckimaciej transfovealmicropulselasertreatmentofcentralserouschorioretinopathywithinsixmonthsofdiseaseonset
AT jaszczukmaciejewskaagnieszka transfovealmicropulselasertreatmentofcentralserouschorioretinopathywithinsixmonthsofdiseaseonset
AT jurskajaskoanna transfovealmicropulselasertreatmentofcentralserouschorioretinopathywithinsixmonthsofdiseaseonset
AT knebamałgorzata transfovealmicropulselasertreatmentofcentralserouschorioretinopathywithinsixmonthsofdiseaseonset
AT grzybowskiandrzej transfovealmicropulselasertreatmentofcentralserouschorioretinopathywithinsixmonthsofdiseaseonset